ARC Medical Inc. files Form D
Sold rose to $NaN (+$50K, +1 investor) in 60 days since the previous filing.
Computed from every Form D fund launch on EDGAR since late 2024, not sampled. Amounts are the stated offering size; indefinite offerings are excluded.
Sold rose from $1M to $1.4M (+$392K) in 22 days since the previous filing.
| Filed | Form | Sold | Investors | Change |
|---|---|---|---|---|
| 2025-03-21 | D/A | $589K | 8 | |
| 2025-04-29 | D/A | $640K | 8 | +$51K |
| 2025-05-20 | D/A | $825K | 9 | +$185K |
| 2025-08-07 | D/A | $901K | 9 | +$77K |
| 2025-10-15 | D/A | $1M | 10 | +$100K |
| 2025-11-06 | D/A | $1.4M | 10 | +$392K |
| 2025-11-10 | D/A | $1.5M | 10 | +$103K |
| 2026-08-10 | D | $118K | 2 | −$1.4M |
| 2026-10-09 | D/A | $167K | 3 | +$50K |
Amount sold and investor count as restated on each of the issuer's Form D filings. A rise since the previous filing is capital closed in between.
Earlier and related filings by the same issuer and sponsor.
Sold rose to $NaN (+$50K, +1 investor) in 60 days since the previous filing.
Sold rose to $NaN (+$103K) in 4 days since the previous filing.
Sold rose to $NaN (+$100K, +1 investor) in 69 days since the previous filing.
| Bruce Hay | Director |
| Deng Mao | Director |
| Christopher Springate | Director, Executive Officer |
Signed by Christopher Springate, CEO.
Relevant to: B2B software & services sales.
The issuer's phone number and address from the filing are shown to subscribers. See plans.